CTLA4 and breast cancer: The safety and efficacy of anti-CTLA-4 monotherapy were evaluated for tremelimumab in a phase II clinical trial (NCT02527434) in advanced TNBC, while for ipilimumab, they were evaluated in a phase I study (NCT01502592) in early-stage BC (Table 11).